Now Open: Seeking participants with CDKL5 deficiency disorder or duplication 15q syndrome for a new clinical study

Ovid Therapeutics is sponsoring a clinical research study called the ARCADE study. ARCADE will assess the effect of OV935, an investigational medicine, on the frequency of seizures in participants with CDKL5 deficiency disorder (CDD) or duplication 15q syndrome (Dup15q). The study will also examine the safety and tolerability of OV935 and how it works within the body.